Neuromolecular Risk Factors for Obesity (PROSPECT)

Detecting Neuromolecular Risk Factors for Obesity

The goal of this project is to characterize the neural and psychological mechanisms that contribute to development of obesity in the early adulthood. We address the neuromolecular risk factors for obesity using multi-modal molecular (positron emission tomography with) and functional (functional magnetic resonance imaging) neuroimaging in a prospective design. Normal weight adolescents with high versus low familial, genetic and psychological risk factors for obesity will be studied and followed for five years.

Study Overview

• Status: Active, not recruiting
• Conditions: Obesity
• Intervention / Treatment: Diagnostic test: fMRI imaging; Diagnostic test: [11C]carfentanil PET scan; Diagnostic test: [18F]FMPEP-d2 PET scan; Diagnostic test: [18F]-FDG PET scan; Diagnostic test: Physical activity measures and fitness tests; Diagnostic test: Laboratory measurements; Diagnostic test: Questionnaires; Diagnostic test: Hyperinsulinemic euglycemic clamp

Detailed Description

Diet, nutrition, and physical exercise are critical factors in the maintenance of good health through the entire life course. However, in most western countries the annual increase in the prevalence and the severity of obesity and physical inactivity is substantial. Early detection of individuals with high risk for obesity is important, because reversing the obese state is very difficult. To prevent and treat obesity, it is necessary to characterize neural mechanisms supporting altered incentive motivation and food intake, and to build a comprehensive model of the interactions between neural, physiological, and psychological factors contributing to development and maintenance of obesity. This obviously calls for novel data analysis techniques allowing fusion analysis of neurobiological, physiological, and behavioural data, as well as screening the critical combination of biomarkers for obesity.

A total of sixty males (30 normal-weight, 30 with risk for developing obesity) are recruited into this prospective study. The subjects will undergo physical examination, physical fitness tests, physical activity measures, body tissue composition measurement, structural and functional magnetic resonance imaging of the brain and body (MRI & fMRI), and positron emission tomography (PET) with ligands [18F]-fluorodeoxyglucose ([18F]-FDG), [18-F]FMPEP, and [11C]carfentanil. Subjects' weight and physical condition will be followed up for 5 years.

In three interconnected work packages (WPs) we test three hypotheses derived from human and animal studies:

1. Altered reward and cognitive control functions in the brain predisposes some individuals to overeating and obesity.
2. Opioid system and reward circuit function provide feasible biomarkers for obesity risk.
3. Mobile tracking and behavioural paradigms tapping reward learning and inhibitory control can be used for unobtrusive and inexpensive detection of risk factors for obesity.

These studies will improve our understanding of the neural and psychological mechanisms of obesity and addictive disorders. This knowledge will translate into crucial knowledge for developing novel risk factor screening procedures, and novel pharmacological and psychological treatments for obesity.

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Finland
  • Turku, Finland, 20521
    • Turku PET Centre (Turku University Hospital)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 35 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

Inclusion criteria for low-risk group:

• Male sex
• Age 20-35 years
• BMI 20-24 kg/m2
• Physical exercise > 4 hrs per week
• No maternal / paternal obesity OR maternal / paternal type 2 diabetes mellitus (T2DM)

Inclusion criteria for high-risk group:

• Male sex
• Age 20-35 years
• BMI 25 - 30 kg/m2
• Maternal / paternal obesity OR maternal / paternal T2DM
• Physical exercise < 4 hrs per week

Exclusion Criteria:

• Any chronic disease or medication that could affect glucose metabolism or neurotransmission
• History of anorexia nervosa, bulimia or other eating disorder (excl. common obesity)
• Smoking of tobacco, taking of snuffs, or use of narcotics
• Abusive use of alcohol
• Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: NON_RANDOMIZED
• Interventional Model: FACTORIAL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Low-risk group; Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.	Diagnostic test: fMRI imaging; Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.; Diagnostic test: [11C]carfentanil PET scan; [11C]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.; Diagnostic test: [18F]FMPEP-d2 PET scan; [18F]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.; Diagnostic test: [18F]-FDG PET scan; Brain and body insuin stimulated glucose uptake is measured with radioligand [18F]-FDG.; Diagnostic test: Physical activity measures and fitness tests; Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.; Diagnostic test: Laboratory measurements; Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.; Diagnostic test: Questionnaires; All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.; Diagnostic test: Hyperinsulinemic euglycemic clamp; Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
ACTIVE_COMPARATOR: High-risk group; Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.	Diagnostic test: fMRI imaging; Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.; Diagnostic test: [11C]carfentanil PET scan; [11C]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.; Diagnostic test: [18F]FMPEP-d2 PET scan; [18F]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.; Diagnostic test: [18F]-FDG PET scan; Brain and body insuin stimulated glucose uptake is measured with radioligand [18F]-FDG.; Diagnostic test: Physical activity measures and fitness tests; Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.; Diagnostic test: Laboratory measurements; Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.; Diagnostic test: Questionnaires; All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.; Diagnostic test: Hyperinsulinemic euglycemic clamp; Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neuromolecular risk score for weight gain	Acquired with combining the measured BMI change in five years to measured alterations in brain function (see below).	Within five study years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Localization of on-going neural activity during various cognitive and affective tasks	Acquired with fMRI imaging	Within one study day
Brain and body glucose uptake	Acquired with PET imaging	Within one study day
Brain and body CB1 availability	Acquired with PET imaging	Within one study day
Brain MOR availability	Acquired with PET imaging	Within one study day
Genes regulating MOR (OPRM1) and D2R (DRD2) expression	Acquired with whole blood sample and DNA/RNA analysis	Within one study week
Genetic risk score from all known obesity-risk genes	Acquired with whole blood sample and DNA/RNA analysis	Within one study week
Behavioural patterns involving dysfunctional reward learning and inhibitory control	Acquired with following questionnaires: assessment of leisure-time physical activity (LTPA), Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire, Pain Sensitivity Questionnaire, DASS-21, PSS-10	Within one study year
Physical activity level	Acquired with Polar M600 GPS Sports Watch that study subjects wear for the measurement period	Within one study week
Maximal physical performance	The subjects will perform a maximal aerobic exercise test on a bicycle ergometer starting at the intensity of 50 W and followed by an increase of 30 W every 2 min until volitional exhaustion. Peak workload will be calculated as an average workload during the last 2 min of the test (weighted average will be used if the final stage is stopped prior the completion) and used as a measure of maximal performance of the subjects	Within one study day
Physical strength	Total physical strenght score is calculated from 1) countermovement jump test with a contact mat (flight time measured - jump height calculated), hand grip strength (measured in Newtons), sit-ups (number of repetitions in 30 s), and back extension (reps in 30 s)	Within one study day
BMI change in five years	Acquired with BMI of the study subjects measured in initial health check-up and once in every study year	Within five study years
Body adiposity	Acquired with BodPod device (Frisard, Greenway, & DeLany, 2005)	Within one study day

Collaborators and Investigators

• Sponsor: Turku University Hospital

Publications and helpful links

General Publications

• Frisard MI, Greenway FL, Delany JP. Comparison of methods to assess body composition changes during a period of weight loss. Obes Res. 2005 May;13(5):845-54. doi: 10.1038/oby.2005.97.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 4, 2017
• Primary Completion (ANTICIPATED): December 1, 2022
• Study Completion (ANTICIPATED): December 1, 2022

Study Registration Dates

• First Submitted: March 5, 2017
• First Submitted That Met QC Criteria: April 3, 2017
• First Posted (ACTUAL): April 10, 2017

Study Record Updates

• Last Update Posted (ACTUAL): December 17, 2021
• Last Update Submitted That Met QC Criteria: December 16, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: Addiction; PET imaging; Cannabinoid receptor; Opioid receptor; fMRI imaging
• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Carfentanil
• Other Study ID Numbers: PROSPECT

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No